WCM/EADO 2021 | The future of adjuvant therapy in melanoma
Christian Blank, MD, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, offers his opinion on the future of adjuvant therapy in melanoma in light of challenges associated with adjuvant therapy and advances being made in neoadjuvant and palliative treatment strategies. He suggests that adjuvant therapy may only be necessary in non-responders to neoadjuvant immunotherapy, which currently makes up approximately 20-30% of patients, although he believes this could be reduced to 5% of patients in the future, once biomarker-driven personalized neoadjuvant therapies are developed. This interview took place during the 10th World Congress of Melanoma in conjunction with the 17th EADO Congress Interactive Virtual Meeting.
Disclosures
Christian Blank, MD, PhD, has participated in an advisory role with BMS, MSD, Roche, Novartis, GSK, AZ, Pfizer, Lilly, GenMab, Pierre Fabre and Third Rock Ventures; has received research funding from BMS, Novartis and NanoString; is a stockholder in Uniti Cars; and is the Co-Founder of Immagene BV.
